Baseline Enrollment Completed for AMRA Medical and Linköping University’s Landmark Liver Disease Study
25 Abril 2024 - 6:50AM
Business Wire
The comprehensive ACCESS-ESLD study aims to validate novel
biomarkers and imaging techniques for screening of hepatocellular
carcinoma and sarcopenia in liver cirrhosis patients using a rapid,
non-invasive clinical surveillance methodology, powered by AMRA’s
MRI-based body composition technology
AMRA Medical, a health informatics and precision medicine
company that is pioneering body composition research through
gold-standard MRI-based analysis platforms, in collaboration with
Link�ping University, is pleased to announce the completion of
baseline enrollment for the innovative ACCESS-ESLD (A Rapid,
Non-invasive, Clinical Surveillance for CachExia, Sarcopenia,
Portal HypertenSion, and Hepatocellular Carcinoma in End-Stage
Liver Disease) study. The nationally-comprised study population
includes 150 liver cirrhosis patients aged 18 and up, with no liver
transplant history or contraindications to performing an MRI
examination, enrolled from one of three Swedish liver care clinics
located in Link�ping, Eksj�, or J�nk�ping. Over a duration of 2
years, patients will be assessed every 6 months with a
comprehensive clinical examination and a whole-body MRI
examination.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240425020008/en/
A rapid, non-invasive, clinical
surveillance for CachExia, sarcopenia, portal hypertension, and
hepatocellular carcinoma in end-stage liver disease: the
ACCESS-ESLD study protocol (Photo: Business Wire)
ACCESS-ESLD will characterize body composition using AMRA’s
proprietary MRI-based health informatics platform to assess muscle
volume (MV) and muscle fat infiltration (MFI), as well as measures
of portal blood flow, liver stiffness, and spleen volume. These
measures will be used to identify and validate risk factors and
biomarkers that indicate current disease severity and predict
future liver-related clinical events in patients with liver
cirrhosis. AMRA’s muscle volume (MV) and muscle fat infiltration
(MFI) measures have previously been shown to independently predict
all-cause mortality1 and comorbid vulnerability2 in patients with
fatty liver disease.
The primary objective of the study will be to determine whether
or not changes in patient MV and MFI, either individually or in
combination, can predict onset of events related to end-stage liver
disease. Additionally, the investigators hope to identify
predictors of mortality, assess non-invasive markers for portal
hypertension, and evaluate how muscle composition and combined body
profile assessments impact diagnosis, physical function and quality
of life in patients with liver disease. The full manuscript
detailing the ACCESS-ESLD study design and objectives was recently
published in the journal BMC Gastroenterology in late 2023.
An indication that poses a significant clinical burden and unmet
need for patients and providers, liver cirrhosis was historically
centered around treatment of complications after they present in
patients. The study investigators hope that the findings of
ACCESS-ESLD will continue the shift in management of liver disease
towards employing more of a preemptive approach, by developing ways
to monitor disease progression and severity while also identifying
novel biomarkers to help predict comorbid diseases/complications in
patients.
“In Sweden, there’s a noticeable rise in liver disease, a
condition often shadowed by social stigma and left neglected.” says
Mattias Ekstedt at the department of health, medicine and caring
sciences (HMV) at Link�ping University. “The ACCESS-ESLD study
promises to enhance our capabilities in detecting and tracking the
progress of individuals living with liver disease, offering hope
for better understanding and management of this health
challenge.”
AMRA’s significant involvement in a hallmark study in the liver
disease space such as this one embodies the company’s commitment to
advancing both research and clinical care. Learn more about AMRA
Medical and how the use of MRI-based body composition analysis is
advancing disease research in liver disease and beyond.
References
1. Linge J, Nasr P, Sanyal A.J, Leinhard O.D, Ekstedt M, Adverse
muscle composition is a significant risk factor for all-cause
mortality in NAFLD, JHEP Reports, 2022: 5(3); 100663.
https://doi.org/10.1016/j.jhepr.2022.100663
2. Linge J, Ekstedt M, Leinhard O.D, Adverse muscle composition
is linked to poor functional performance and metabolic
comorbidities in NAFLD. JHEP Reports, 2021: 3(1);100197.
https://doi.org/10.1016/j.jhepr.2020.100197
About AMRA Medical
AMRA Medical is a health informatics and precision medicine
company that is pioneering body composition analysis, providing
cutting-edge solutions to advance both clinical research and
patient care initiatives. AMRA's gold-standard technology delivers
multiple fat and muscle biomarkers - derived simply from rapid
whole-body MRI scans. AMRA is committed to driving transformative
care and simplifying vital decision-making in both research and
clinical care settings by offering support services via their
innovative platform.
Learn more about AMRA Medical’s MRI-based solutions at
https://amramedical.com/solutions, or connect with our team of
experts for a detailed discussion at info@amramedical.com.
Follow AMRA on LinkedIn for the latest updates in body
composition and precision medicine.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240425020008/en/
AMRA Medical Marie B�rjesson, VP Brand & Marketing 0046 70
628 1977 marie.borjesson@amramedical.com